Feasibility of Outpatient Induction Chemotherapy for Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
PRIMARY OBJECTIVES:
I. Assess the feasibility of outpatient induction therapy for acute myeloid leukemia (AML)
or advanced myelodysplastic syndrome (MDS) by examining whether > 50% of patients treated as
outpatients can complete chemotherapy without being admitted to hospital or < 5% of patients
die within 14 days of beginning outpatient chemotherapy.
OUTLINE:
Patients receive outpatient induction chemotherapy.
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Rate of hospital admission
During the 4-7 days of outpatient chemotherapy
No
Pamela Becker
Principal Investigator
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
United States: Federal Government
7910
NCT01807091
May 2013
Name | Location |
---|---|
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Seattle, Washington 98109 |